{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:12:34Z","timestamp":1784229154118,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00184","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T14:22:49Z","timestamp":1583158969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Population Pharmacokinetics of Caspofungin and Dosing Optimization in Children With Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.3389","volume":"11","author":[{"given":"Chang-He","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Liu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Peng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Lan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13054-016-1594-9","article-title":"Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients","volume":"21","author":"Aguilar","year":"2017","journal-title":"Crit. Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02198-16","article-title":"Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis","volume":"61","author":"Castro","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive Aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/s1473-3099(03)00801-6","article-title":"Epidemiology of Candida species infections in critically ill non-immunosuppressed patients","volume":"3","author":"Eggimann","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo. Clin. Proc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1128\/AAC.00905-10","article-title":"Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients","volume":"55","author":"Li","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/ejh.13214","article-title":"Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide","volume":"102","author":"Mariotti","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s12325-017-0534-7","article-title":"Comparison of efficacy and safety of caspofungin versus micafungin in pediatric allogeneic stem cell transplant recipients: a retrospective analysis","volume":"34","author":"Maximova","year":"2017","journal-title":"Adv. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jiac.2017.12.015","article-title":"Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation","volume":"24","author":"Morita","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijantimicag.2017.05.013","article-title":"Dosing of caspofungin based on a pharmacokinetic\/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration","volume":"51","author":"Perez-Pitarch","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1128\/JCM.00308-13","article-title":"Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic andTemporal Trends of Antifungal Resistance","volume":"51","author":"Pfaller","year":"","journal-title":"J. Clin. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","volume":"56","author":"Roger","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.med.59.062906.071602","article-title":"Advances in antifungal therapy","volume":"59","author":"Sable","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1128\/AAC.03324-14","article-title":"Pharmacokinetics and safety of intravitreal caspofungin","volume":"58","author":"Shen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/1040841X.2015.1068271","article-title":"Caspofungin: pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes","volume":"42","author":"Song","year":"2016","journal-title":"Crit. Rev. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1345\/aph.1M139","article-title":"A clinical review of echinocandins in pediatric patients","volume":"44","author":"VandenBussche","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00248-19","article-title":"Body surface area-based dosing regimen of caspofungin in children: a population pharmacokinetics confirmatory study","volume":"63","author":"Yang","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T14:22:50Z","timestamp":1583158970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":22,"alternative-id":["10.3389\/fphar.2020.00184"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00184","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"article-number":"184"}}